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Background: Cardiac sarco(endo)plasmic reticulum calcium ATPase-2 (SERCA2) plays one of the central roles in
myocardial contractility. Both, SERCA2 mRNA and protein are reduced in myocardial infarction (MI), but the
correlation has not been always observed. MicroRNAs (miRNAs) act by targeting 3'-UTR mRNA, causing translational
repression in physiological and pathological conditions, including cardiovascular diseases. One of the aims of our
study was to identify miRNAs that could influence SERCA2 expression in human MI.
Results: The protein SERCA2 was decreased and 43 miRNAs were deregulated in infarcted myocardium compared
to corresponding remote myocardium, analyzed by western blot and microRNA microarrays, respectively. All the
samples were stored as FFPE tissue and in RNAlater. miRNAs binding prediction to SERCA2 including four prediction
algorithms (TargetScan, PicTar, miRanda and mirTarget2) identified 213 putative miRNAs. TAM and miRNApath
annotation of deregulated miRNAs identified 18 functional and 21 diseased states related to heart diseases, and
association of the half of the deregulated miRNAs to SERCA2. Free-energy of binding and flanking regions (RNA22,
RNAfold) was calculated for 10 up-regulated miRNAs from microarray analysis (miR-122, miR-320a/b/c/d, miR-574-
3p/-5p, miR-199a, miR-140, and miR-483), and nine miRNAs deregulated from microarray analysis were used for
validation with qPCR (miR-21, miR-122, miR-126, miR-1, miR-133, miR-125a/b, and miR-98). Based on qPCR results, the
comparison between FFPE and RNAlater stored tissue samples, between Sybr Green and TaqMan approaches, as
well as between different reference genes were also performed.
Conclusion: Combing all the results, we identified certain miRNAs as potential regulators of SERCA2; however,
further functional studies are needed for verification. Using qPCR, we confirmed deregulation of nine miRNAs in
human MI, and show that qPCR normalization strategy is important for the outcome of miRNA expression analysis
in human MI.
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A growing body of evidence has revealed that dysfunc-
tion of 3'- and 5'-untranslated regions (UTRs) is linked
to the pathophysiology of variety of diseases. Both UTRs
are important as regulatory elements of mRNA
translation [1]. One of the negative regulators of mRNA
translation are small non-coding RNAs, microRNAs
(miRNAs) that bind to 3'-UTR of target mRNA. By
binding to target mRNA, miRNAs have been found to* Correspondence: damjan.glavac@mf.uni-lj.si
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reproduction in any medium, provided the orregulate a variety of physiological functions and contrib-
ute to various diseases, including ischemic heart diseases
[2]. It has been suggested that some parts of the con-
served regions of the 3'-UTRs of SERCA2 might repre-
sent post-transcription binding sites for miRNAs [3].
SERCA2 is muscle-specific sarco(endo)plasmic reticulum
calcium ATPase-2, which promotes cardiac relaxation and
contractility. During every heartbeat, a pulse of calcium is
released from the sarcoplasmic reticulum (SR) into the
cytoplasm of cardiac muscle cells through a calcium
release channel (RyR, ryanodine receptor), thus triggering
muscle contraction. During relaxation, SERCA2 re-
sequesters the calcium back into the internal sarcoplasmicral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Western blot results of SERCA2 expression in the
infarcted tissue and corresponding remote myocardium.
SERCA2 (~100 kDa) is under-expressed in the infarcted tissue when
compared to corresponding remote myocardium. GAPDH (~37 kDa),
used as internal control, showed similar expression in infarcted and
remote myocardium of patients with myocardial infarction. Legend:
I, infarcted tissue, R, corresponding remote myocardium.
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of calcium [4]. SERCA2 pre-mRNA is edited depending
on the cellular type. Due to different alternative splicing,
the last exons of SERCA2 pre-mRNA produce different
mRNAs, which differ at the 3´-UTR regions and encode
for SERCA2a, SERCA2b and SERCA2c isoforms. In the
heart, SERCA is mainly represented by the SERCA2a iso-
form, which is expressed in the heart and slow-twitch
skeletal muscle [3,5]. SERCA2b, ubiquitously expressed in
all tissues, may at least partially replace SERCA2a func-
tion [6].
Decreased expression of the SERCA2 is one of the key
features of cardiac myocyte dysfunction in both experi-
mental and human heart failure as well as in myocardial
infarction MI [3,4,6,7]. It is believed that this decrease
contributes to abnormal contractility in post-infarction
rat myocytes and that increased expression of SERCA2
could improve myocardial contractility in cardiovascular
diseases [8,9]. It has been shown that the main regula-
tors of SERCA2 protein and cardiac contractility are
phospholamban (PLN) in the ventricles and sarcolipin
(SLN) in the atria [3]. A simultaneous decrease in
SERCA2 mRNA and protein levels is not always
observed [7], and there remain gaps in understanding
regulation of SERCA2 by PLN and SLN in the heart [4].
Since functionally critical genes that are spatially
expressed are stringently regulated by miRNAs [10], was
the aim of our study to test for miRNA and SERCA2 ex-
pression in infarcted myocardium compared to corre-
sponding remote myocardium of patients with MI, and
defined by target prediction algorithms those miRNAs
with a potential influence on SERCA2 mRNA 3'-UTR.
Differentially expressed miRNAs were further investi-
gated using bioinformatic approaches as possible regula-
tors of SERCA2 protein regulators (PLN, SLN). We also
compared the miR-26b and RNU6B as reference genes
(RGs), both of which were used as endogenous controls
in our previous study [11]. Two different approaches
were used (TaqMan and Sybr Green), as well as two dif-
ferent types of tissues (RNAlater, FFPE).
Results
Western blot
In 4 out of 6 tested samples of infarcted tissues, it
was possible to extract enough proteins in a defined
volume to get comparable result using western blot
(20 μg). In all four tested tissue samples we observed
decreased SERCA2 protein expression in the
infarcted tissue (I) when compared to corresponding
remote (R) myocardium. The GAPDH protein, used
as endogenous control, showed no change in the ex-
pression between infarcted tissue and corresponding
remote myocardium. The results are summarized in
Figure 1.MicroRNA microarray results
Microarray data are deposited to the Gene Expression
Omnibus public depository (GSE17304). MicroRNA
microarray expression analysis revealed 43 differentially
expressed miRNAs in infarcted tissue when compared to
corresponding remote myocardium. Ten of the 43 differ-
entially expressed miRNAs showed up-regulation. The
results are summarized in Table 1. Unsupervised hier-
archical clustering was performed using all miRNAs
being differentially expressed in microarray analysis. The
results are summarized in Figure 2. Since SERCA2 pro-
tein showed down-regulation in infarcted tissue com-
pared to corresponding remote myocardium, the
resulting 10 miRNAs, which showed up-regulation, were
subject to further bioinformatics analysis.
We further compared our results to our previous
study based on microarray analysis [11], where the
miRNA expression in infarcted tissue was calculated
relative to the miRNA expression in healthy human
hearts (independent groups of samples). Of 43 differen-
tially expressed miRNAs in infarcted tissue compared to
remote myocardium, 20 miRNAs showed similar expres-
sion also when infarcted tissue was compared to healthy
human hearts, 4 were specifically differentially expressed
in the present study, and 19 showed higher difference in
expression in the present study. The results are summar-
ized in Table 1.
Bioinformatic analysis of miRNAs
miRNA prediction
Using four different available prediction algorithms,
namely TargetScan [12], PicTar [13], mirTarget2
included in miRDB [14], and miRanda [15] included in
MicroCosm Targets (former miRBase) [16] and in
microrna.org [17], 213 miRNAs were predicted for
binding to 3'-UTR mRNA SERCA2. However, target
prediction programs did not distinguish between iso-
forms SERCA2a and SERCA2b. Of 213 predicted
Table 1 Differentially expressed miRNAs in infarcted tissue compared to corresponding remote myocardium, their
classification (from miRBase) and prediction of targeting SERCA2 (PicTar, TargetScan, miRanda, mirTarget2)
miRNA average
log2




let-7b 0.04 −0.32 Yes let-7 22: let-7a-3, miR-4763; intronic
let-7c −0.87 −0.88 Yes let-7 21: miR-99a; intronic
let-7d −1.34 −1.33 Yes let-7 9: let-7a-1, let-7f-1; intronic
let-7g −1.50 −1.67 Yes let-7 3: as single gene; intronic
miR-1 −3.28 −1.89 No miR-1 18: miR-133a-1; intronic
20: miR-133a-2; intronic
miR-122 3.28 ND No miR-122 18: miR-3591; intergenic
miR-125a-5p −1.53 −1.46 No miR-125 19: let-7e, miR-99b; intronic
miR-125b −0.44 −0.47 No miR-125 11: as single gene; intronic
miR-126 −2.00 −0.50 No miR-126 9: as single gene; intronic
miR-133a −1.52 ND No miR-133 18: miR-1-2; intronic
20: miR-1-1; intronic
miR-133b −1.53 ND No miR-133 6: miR-206; intronic
miR-140-3p 0.32 ND No miR-140 16: as single gene; intronic
miR-143 −0.26 ND No miR-143 5: miR-145; intergenic
miR-145 −0.79 ND No miR-145 5: miR-143; intergenic
miR-150 −1.63 −1.60 No miR-150 19: as single gene; intergenic
miR-16 −0.03 ND No miR-15 13: miR-15a; intronic
3: miR-15a; intronic
miR-195 −0.51 −1.37 Yes miR-15 17: miR-497; intronic
miR-197 −0.57 ND No miR-197 1: as single gene; intergenic
miR-199a-3p 0.39 ND No miR-199 19: as single gene; intronic
1: miR-199a-2, miR-3120, miR-214; intronic
miR-19b −2.36 ND Yes miR-19 13: miR-17, miR-18a, miR-19a,
miR-20a, miR-92a-1; intergenic
X: miR-106a, miR-18b, miR-20b,
miR-92a-2, miR-363; intergenic
miR-21 −0.05 ND No miR-21 17: as single gene; intergenic
miR-23a −1.71 −0.20 No miR-23 19: miR-27a, miR-24-2; intergenic
miR-26a −1.50 −0.54 No miR-26 3: as single gene; intronic
12: as single gene; intronic
miR-27a −1.97 −1.60 No miR-27 19: miR-23a, miR-24-2; intergenic
miR-27b −2.18 −1.19 No miR-27 9: miR-23b, miR-24-1, miR-3074; intronic
miR-29a −1.40 ND Yes miR-29 7: miR-29b-1; intergenic
miR-29c −2.28 ND No miR-29 1: miR-29b-2; intergenic
miR-30a −2.23 −1.25 Yes miR-30 6: as single gene; intronic
miR-30b −3.03 −2.01 Yes miR-30 8: miR-30d; intergenic
miR-30c −2.70 −2.08 Yes miR-30 1: miR-30e; intronic
6: as single gene; intronic
miR-30d −1.31 ND Yes miR-30 8: miR-30b; intergenic
miR-30e −2.71 ND Yes miR-30 1: miR-30c-1; intronic
miR-320a 2.37 0.98 No miR-320 8: as single gene; intergenic
miR-320b 2.24 0.98 No miR-320 1: two copies as single gene; one intronic
and one intergenic
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Table 1 Differentially expressed miRNAs in infarcted tissue compared to corresponding remote myocardium, their
classification (from miRBase) and prediction of targeting SERCA2 (PicTar, TargetScan, miRanda, mirTarget2) (Continued)
miR-320c 2.27 0.98 No miR-320 18: two copies as single gene; intronic
miR-320d 2.13 0.98 No miR-320 13: as single gene; intergenic
X: as single gene; intergenic
miR-378 −1.66 ND No miR-378 5. as single gene; intronic
miR-483-5p 2.92 ND No miR-483 11: as single gene; intronic
miR-499-5p −2.94 −3.36 Yes miR-499 20: miR-499a; intronic
miR-574-3p 2.25 2.46 Yes miR-574 4: as single gene; intronic
miR-574-5p 2.17 3.18 No miR-574
miR-98 −1.76 −3.10 Yes let-7 X: let-7f; intronic
Legend: *, results from previous microarray study [11], where infarcted tissue was compared to healthy adult hearts (independent groups of samples); ND, not
determinate; chr, chromosome.
Figure 2 Hierarchical clustering analysis of the log2 value of differentially expressed miRNAs in myocardial infarction. Dual colour
experiments and swap-dye were performed, using Cy3 and Cy5 to compare miRNAs expression in infarcted tissue and corresponding remote
myocardium. Statistical analysis and hierarchical clustering was performed using Acuity 4.0 analytical software. The results are displayed in a heat
map. The legend on the right indicates the miRNA shown in the corresponding row, all of which are human specific. The bar code on the
bottom shows the colour scale of the log2 value. Each column represents data from one microarray. The heat map was constructed of 43
miRNAs dysregulated in all of the microarrays performed.
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http://www.biomedcentral.com/1471-2164/13/552miRNAs, 136 corresponded to an isoform SERCA2b and
74 to an isoform SERCA2a. Significantly, TargetScan5.1
gave no results for isoform SERCA2b, and mirTarget2
predicted only one miRNAs to target SERCA2b. In the
case of SERCA2a, all of the used algorithms predicted
miRNAs (Additional file 1: Table S1). Of all 213 miRNAs
predicted to target SERCA2, 15 were differentially
expressed in human MI (Table 1).
Free-energy analysis
It has been recently demonstrated with the majority
of miRNA-validated targets that miRNAs preferentially
bind to 3'-UTR sites that do not have complex sec-
ondary structures and are located in accessible regions
of the mRNA based on favourable thermodynamics.
Ten miRNAs were used for further in silico validation:
one predicted by using above programs with elevated
expression in microarray analysis (hsa-miR-574-3p;
miRBase accession number: MIMAT0003239) and
nine up-regulated in microarray analysis but not pre-
dicted by the algorithms used (hsa-miR-122, hsa-miR-
199a-3p, hsa-miR-140-3p, hsa-miR-320a, hsa-miR-
320b, hsa-miR-320c, hsa-miR-320d, hsa-miR-483-5p,




respectively). Although is believed that SERCA2a is
the major isoform in the heart, our further analysis
focused on both isoform SERCA2a and SERCA2b,
since primary antibody used in our western blot ana-
lysis did not distinguish between isoform SERCA2a
and SERCA2b. All results for SERCA2a and SER-
CA2b are summarized in Table 2 and Table 3,
respectively.
Using criteria postulated by Zhao et al. (2005) [18], we
predicted binding sites in 3´-UTR of SERCA2b and SER-
CA2a mRNA for up-regulated miRNAs. Using RNA22
algorithm [19], some miRNAs were predicted to have
over 10 potential binding sites either in SERCA2a or
SERCA2b. In case of SERCA2b, 13 binding sites were
predicted for hsa-miR-320a/b, 12 for hsa-miR-320c/d, 15
for hsa-miR-574-5p and 20 for hsa-miR-122. In case of
SERCA2a, 16 binding sites were predicted for hsa-miR-
574-5p. We therefore presented those with the highest
difference (at least 10 kcal/mol) between the potential
binding site and the 70 nt flanking 3' and 5' of predicted
binding site based on calculation using RNAfold [20].
Large proportion of binding sites is located in certain
positions in 3'-UTRs of corresponding SERCA2a and
SERCA2b. In SERCA2a, there are 7 “hot-spot” locations
for miRNA binding and in SERCA2b there are 9 “hot-
spot” locations. For most of predicted binding sites there
is more than one predicted miRNA (cooperativity), andthis is further attenuated by more than one binding site
for one miRNA (multiplicity). Most of predicted miR-
NAs have at least one binding site with perfect compli-
mentarity to seed region.
miRNA annotation and functional classification
Analysis using miRBase revealed that differentially
expressed miRNAs belongs to 25 miRNA Gene family,
and at least one gene copy of 25 differentially expressed
miRNAs is clustered. Further, the 4 clusters are fully
represented among differentially expressed miRNAs.
The results are summarized in Table 1.
TAM tool [21] was used to annotate differentially
expressed miRNAs in the mean of function and disease
associations. Among 35 defined functions for differen-
tially expressed miRNAs, 18 are related to heart diseases
(Additional file 2: Table S2). Further, differentially
expressed miRNAs are related to 136 different disease
outcomes, 21 are related to heart diseases (Additional
file 3: Table S3).
Finally, miRNApath [22] revealed that calcium signal-
ling pathway includes 175 genes, and 468 miRNAs regu-
lating these genes. Of these, 95 miRNAs are associated
with SERCA2, 19 miRNAs with PLN, and 21 miRNAs
with SLN. Of differentially expressed miRNAs in our
study, 18 are according to miRNApath related to
SERCA2, none is related to PLN, and three are related
to SLN. In summary, only miR-30a/e and miR-145 are
differentially expressed and related to SERCA2 as well as
to its regulator SLN (data not shown).
Quantitative real-time PCR
Using two different qPCR technologies, we validated the
expression of nine miRNAs. Sybr Green technology was
used to validate: miR-122, which was specifically
expressed on present microarrays compared to our pre-
vious study [11] and it showed the highest up-
regulation; miR-21 and miR-126, which are in addition
to muscle-specific miR-1 and miR-133 the most com-
mon miRNAs involved in heart diseases; miR-125a/b,
which are according to TAM tool involved in myocardial
remodelling after MI. TaqMan based approach was
used to validate miR-98, which was one of the few
miRNAs overlapping target prediction and is according
to TAM tool involved in hypertrophy; and miR-1 and
miR-133a/b, muscle-specific miRNAs.
In addition to microarray validation, the qPCR meth-
odology was used to test several presumptions. First,
miR-26b was tested as RG in comparison to RNU6B.
Both were used as RGs in our previous study [11], using
miR-26b as RG in TaqMan based approach and RNU6B
as RG in Sybr Green approach. In present study, both
were used in TaqMan as well as in Sybr Green technol-
ogy. The expression of RNU6B showed relative stability
Table 2 miRNAs with predicted influence on SERCA2a expression
MicroRNA ΔG binding
(Kcal mol-1)
ΔG 70 nt flanking 3’
of predicted binding
site (Kcal mol-1)









miR-122 −22.0 −14.9 −11.2 671-692 partially (1–6)
miR-199a-3p −32.1 −9.1 −14.1 76-97 no
−30.7 −11.1 −6.9 535-556 no
−24.3 −9.2 −6.9 705-726 no
−22.0 −7.6 −11.3 259-280 no
−20.5 −10.1 −6.6 26-47 no
miR-320a −24.6 −10.9 −7.1 117-138 partially (1–5, 7–12)
−21.7 −6.9 −11.1 536-557 partially (1–2, 4–8)
−24.8 −12.3 −11.4 505-526 partially (1–4, 7–8)
−25.5 −6.9 −12.9 229-250 no
−20.5 −8.5 −5.3 711-732 no
miR-320b −24.6 −10.9 −7.1 117-138 partially (1–5, 7–12)
−21.7 −6.9 −11.1 536-557 partially (1–2, 4–8)
−25.8 −12.3 −11.4 505-526 partially (1–4, 7–8)
−25.5 −6.9 −12.9 229-250 no
miR-320c −23.2 −6.9 −12.9 230-249 no
−23.3 −12.3 −11.4 507-526 partially (1–4, 7–8)
−19.5 −7.7 −5.3 713-732 no
miR-320d −24.4 −10.1 −7.1 120-138 partially (1–5, 7–13)
−19.4 −6.9 −11.1 539-557 partially (1–2, 4–8)
−22.8 −6.9 −12.9 231-249 no
−23.1 −12.3 −11.4 508-526 partially (1–4, 7–8)
−19.2 −6.4 −5.3 714-732 no
miR-483-5p −24.7 −9.8 −6.8 122-143 no
−24.1 −7.6 −6.3 708-729 no
miR-574-3p −27.8 −8.6 −5.3 725-746 yes
−32.5 −7.3 −9.7 37-58 partially (2–5, 7–13)
miR-574-5p −22.7 −7.3 −11.0 465-487 yes
−25.6 −14.5 −14.1 664-686 no
−30.2 −12.5 −0.3 740-762 no
−22.9 −8.0 −12.3 413-435 no
−21.6 −7.8 −11.1 364-386 no
miR-140-3p −19.1 −11.3 0.3 746-766 partially (1–4)
−20.2 −7.3 −9.7 38-58 yes
−24.2 −7.7 −5.3 713-733 yes
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sue samples. When the RNU6B expression using Sybr
Green (performed on Rotor Gene Q) was compared to
the results from same tissue from previous study (per-
formed on ABI7900), the expression showed same stabil-
ity, except that the Cq-values were higher in previous
study for 2.38 ± 0.39. miR-26b showed similar expression
to RNU6B in RNAlater stored tissue (TaqMan or SybrGreen) as well as in FFPE samples (TaqMan), but it not
seems to be suitable as RG, when validating FFPE using
Sybr Green (SD is much higher when using miR-26b in
comparison to RNU6B). The results are summarized in
Table 4.
Second, we compared Sybr Green and TaqMan ap-
proach. The results of miR-26b relatively to RNU6B were
similar across the samples using either Sybr Green or
Table 3 miRNAs with predicted influence on SERCA2b expression
MicroRNA ΔG binding
(Kcal mol-1)
ΔG 70 nt flanking 3’
of predicted binding
site (Kcal mol-1)









miR-122 −24.9 −9.9 −8.7 313-334 no
−23.7 −3.0 −8.2 788-809 no
−21.5 −0.2 −9.5 496-517 no
−19.3 −8.2 −7.5 253-274 no
−19.3 −3.5 −5.2 476-497 no
−19.3 −6.3 −9.0 458-479 no
−18.1 −4.3 −8.3 151-172 no
miR-199a-3p −22.0 −4.9 −9.5 380-401 yes
−21.0 −3.1 −11.1 487-508 yes
−18.6 −8.3 −3.9 59-80 yes
−18.1 −7.5 −8.3 251-272 no
miR-320a −21.2 −9.9 −9.3 405-426 no
−21.8 −9.0 0.3 798-819 no
−21.2 −4.7 −9.8 65-86 partially (1–4)
−23.7 −8.2 −8.2 687-708 no
−21.8 −9.1 −11.9 123-144 partially (1–6)
miR-320b −21.2 −9.9 −9.3 405-426 no
−21.8 −9.0 0.3 798-819 no
−21.2 −4.7 −9.8 65-86 partially (1–4)
−23.7 −8.2 −8.2 687-708 no
−21.8 −9.1 −11.9 123-144 partially (1–6)
miR-320c −19.1 −8.0 0.3 800-819 no
−24.0 −12.4 −8.2 689-708 no
−21.1 −11.4 −9.2 650-669 no
miR-320d −23.4 −13.2 −8.2 690-708 no
−24.3 −12.2 −9.0 709-727 partially (1–4, 6–7)
miR-483-5p −23.8 −13.1 −9.0 705-726 no
−21.8 −4.7 −8.5 63-84 no
−22.7 −9.1 −9.3 121-142 no
−20.3 −8.2 −3.0 789-810 Partially (1, 3–6, 8)
miR-574-3p −22.9 −8.2 −6.5 347-368 No
−21.2 −2.7 −11.3 96-117 no
miR-574-5p −21.7 −8.6 −8.0 263-285 No
−23.4 −4.9 −3.5 479-501 No
−18.2 −3.3 −3.5 12-34 No
−20.5 −9.0 0.3 797-819 Partially (1–5, 7)
miR-140-3p −19.9 −8.2 −6.5 348-368 yes
−20.5 −9.9 −3.5 484-504 No
−19.7 −8.7 0.3 799-819 no
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stored tissue samples (data not shown).
Third, the comparison between RNAlater and FFPE
tissue samples has been performed. The results aresummarized in Table 5. Using both technologies (Taq-
Man and Sybr Green), we confirmed most of the micro-
array results using RNU6B as RG, as well as using miR-
26b (only in case of TaqMan approach). Both was true
Table 4 Stability of reference genes in qPCR of tested samples
Technology TaqMan Sybr Green
RG tested miR-26b RNU6B RNU48 miR-26b RNU6B
Measurements Cq SD Cq SD Cq SD Cq SD Cq SD
FFPE 26.67 2.95 32.56 2.41 29.36 2.11 28.56 2.99 19.83 1.58
RNAlater 23.63 0.91 30.24 1.27 25.71 0.96 24.46 1.21 14.66 1.22
Legend: RG, reference gene; Cq, tershold/quantification cycle; SD, standard deviation; FFPE, formalin fixed paraffin-embeded tissue; RNAlater, RNAlater stored
samples.
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some discrepancies can be seen between RNAlater and
FFPE samples using Sybr Green approach. It can be also
noted from Table 5 that in the case of Sybr Green, using
miR-26b as RG for FFPE samples gives different results
from using RNU6B as RG. RNU6B as RG with FFPE
samples (Sybr Green) is in accordance to microarray
results, and only expression of miR-122 relatively to
miR-26b in FFPE samples corresponds to microarray
results (Sybr Green). In contrast, results from RNAlater
samples are similar between those that use RNU6B as
RG and those that use miR-26b as RG.
Statistical analysis revealed that miR-1, miR-133a/b
and miR-98 expression based on qPCR results is in ac-
cordance to microarray results, that are down-regulated
in infracted compared to corresponding remote myocar-
dium, but statistical significance is dependent of RG
used (Table 5). In contrast, expression of miR-1 and
miR-133a/b is always in statistical significant correlation
to each other not dependent of RG used (data not
shown). The same is true for expression of miR-125a-5p
and miR-125b. Expression of miRNAs (miR-21, miR-
125a/b, miR-122 and miR-126) is dependent of RG and
type of tissue. The expression of all five miRNAs was in
accordance to microarray results in FFPE, when RNU6B
was used as RG. In contrast, comparing miR-26b and
RNU6B as RG, the different outcomes were detected in
FFPE samples, but similar (and different from micro-
array study) in RNAlater stored samples. As well asTable 5 Ratios of differentially expressed miRNAs in infarcted
TaqMan
miR-1 miR-133a miR-133b miR-98
FFPE RNU48 0.10 1.24 0.25 0.36
RNAlater RNU48 0.47 0.46 0.39 0.62
FFPE RNU6B 0.11 0.68 0.29 0.41
RNAlater RNU6B 0.22 0.22 0.18 0.29
FFPE miR-26b 0.20 1.25 0.53 0.74
RNAlater miR-26b 0.78 0.77 0.64 1.02
microarray results 0.10 0.35 0.35 0.30
The ratios are calculated according to the efficiency corrected model [46]. Expressio
calculated as a proportion of the expression in corresponding remote myocardium.
paraffin-embedded tissue; RNAlater, samples stored in RNAlater; RNU48, the small R
the miR-26b is used as RG.previously described [23] we observed superior sensitiv-
ity of qPCR over microarray analysis and did not observe
significant variation potentially introduced by reverse
transcription.
Discussion
In our study, we showed a reduced expression of protein
SERCA2 in infarcted tissue when compared to corre-
sponding remote myocardium of patients with MI.
These results are in accordance with previously demon-
strated decrease in SERCA2 mRNA and protein levels in
ischemic-reperfused heart and animal models of myocar-
dial ischemia [7]. A decrease in content and activity of
SERCA2 is also observed during ageing [4]. To eliminate
misinterpretation of western blot results due to different
ages of our patients, we did not compare SERCA2 in re-
mote myocardium and infarcted tissue of patients with
MI to healthy adult hearts. Since simultaneous decrease
in SERCA2 mRNA and protein levels is not always
observed [7], and there remain gaps in understanding
regulation of SERCA2 by its protein regulators [4], we
presumed that SERCA2 might be regulated by miRNAs.
MicroRNA microarray expression analysis revealed 43
differently expressed miRNAs in infarcted tissue when
compared to corresponding remote myocardium, 10 of
these showing up-regulation (speculatively being
involved in SERCA2 regulation). According to miRNA-
path analysis of calcium signalling pathway, approx. half
of differentially expressed miRNAs are related totissue using TaqMan based and Sybr Green approach
Sybr Green
miR-21 miR-122 miR-125a-5p miR-125b miR-126
nd nd nd nd nd
nd nd nd nd nd
0.59 1.71 0.49 0.44 0.29
1.65 0.18 1.04 1.18 0.99
5.03 14.52 4.21 3.73 2.49
2.64 0.29 1.67 1.90 1.59
0.97 9.71 0.35 0.74 0.25
n in remote myocardium is set at one, and expression in infarcted tissue is
Further, three different genes were used as RGs. Legend: FFPE, formalin-fixed
NA RNU48 is used as RG; RNU6B, the small RNA RNU6B is used as RG; miR-26b,
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our previous study based on microarray analysis [11],
where the miRNA expression in infracted tissue was cal-
culated relative to the miRNA expression in healthy
human hearts (independent groups of samples), only half
of miRNAs showed similar expression in the present
study, suggesting specifically expressed miRNAs in
infracted tissue as well as in remote myocardium com-
pared to healthy adult hearts. This is in accordance to
recent findings that some miRNAs in the non-infarcted
area might also participate in the pathophysiology re-
sponse to MI [24].
SERCA2 has two major isoforms, SERCA2a and SER-
CA2b, both of which are expressed in heart from early
developmental stages, although it is believed that SER-
CA2a is the major isoform expressed in the heart [5].
Using four different available prediction algorithms, 213
miRNAs were predicted for binding to 3'-UTR mRNA
SERCA2; however, used algorithms did not distinguish
between SERCA2 isoforms. Of predicted miRNAs, two
times more corresponded to an isoform SERCA2b than
to an isoform SERCA2a, and only approx. 10% were dif-
ferentially expressed in infarcted tissue compared to re-
mote myocardium. Finally, only one of predicted and
differentially expressed was up-regulated (miR-574-3p).
miR-574-3p was also predicted to target ATP2A2 in
our previous study, and has been elevated in infarcted
compared to healthy adult hearts [11]. We therefore
used this and other up-regulated miRNAs to search for
potential binding using algorithm RNA22. The inter-
action of miRNA:mRNA usually occurs via non-strict
base pairing, and the most important should be match-
ing to the 1–8 nucleotides from the 5´ end of miRNA
(“seed” region). miRNA-mRNA binding may also occur
in other ways [25]. Some features of miRNA:mRNA
binding have been implicated in bioinformatics and ex-
perimental approaches, but most of the target sites iden-
tified by available tools are based on seed region
complimentarity, therefore might be biased against the
one class of binding sites. Since the majority of a given
mRNA sequence is highly structured and local RNA ac-
cessibility of the binding site may be a critical feature of
miRNA target recognition [18], we determined the free-
energy (ΔG) of the miRNA:mRNA binding. We further
tested all 10 up-regulated miRNAs for free-energy of 70
nt of 5´ and 3´ of the predicted binding sites to test
whether the predicted binding sites are located in a re-
gion of very high free energy, suggesting a locally access-
ible site. Complex RNA secondary structures may
prevent miRNA/mRNA interactions and may have in-
hibitory effects on miRNA:mRNA interactions. Repres-
sion of mRNAs may be also increased by multiplicity
(several binding sites in a transcript for a single miRNA)
and cooperativity (several miRNAs bind to a singletranscript) [25]. In line with that, several miRNAs were
predicted for binding to the same positions of 3´-UTR
SERCA2 (7 predicted miRNAs binding positions for
SERCA2a, and 9 predicted miRNAs binding positions
for SERCA2b), and for the majority of the predicted
miRNAs there was more than one putative binding site.
Most of predicted miRNAs have at least one binding site
with perfect complimentarity to seed region.
As previously described, some of the up-regulated and
in silico validated miRNAs have been already related to
cardiovascular diseases [26]. In addition to miR-122,
which was specifically expressed on present microarrays
compared to our previous study [11] and is according to
recent report down-regulated in plasma of patients with
MI [27], miR-574 and miR-140 have not been yet
described as involved in cardiovascular pathology. Other
up-regulated and in silico validated miRNAs were miR-
199a, four members of miR-320 family and miR-483.
miR-199a was described as involved in the maintenance
of cell size in cardiomyocytes [28], and as a master regu-
lator of a hypoxia-triggered pathway [29]. miR-320 was
shown to be involved in the regulation of cardiac ische-
mia/reperpusion injury through targeting heat-shock
protein 20: over-expression enhanced cardiomyocyte
apoptosis, whereas knockdown was cytoprotective [30].
miR-483 was described as in vitro regulator of angiogen-
esis through serum response factor [31].
Further analysis using miRBase revealed that 43 differ-
entially expressed miRNAs belong to 25 miRNA Gene
family, and that half of differentially expressed miRNAs
is clustered. Further, the 4 clusters are fully represented
among differentially expressed miRNAs. This is expected
since many genetically clustered and co-transcribed
miRNAs are often expressed at different levels [26].
TAM tool was used to annotate 43 differentially
expressed miRNAs; more than half of the defined func-
tions are related to heart pathology and physiology, as
well as to 21 disease outcomes related to heart path-
ology. Based on annotation we used nine miRNAs to
validate microarray results, using two different qPCR
technologies.
Most of the validated miRNAs have been already
described as being involved in post-infarct remodelling
[32]. Using TaqMan based technology; the miR-1 and
miR-133 were used to compare present study to our-
previous research [33] and confirmed up-regulation of
miR-1 in remote myocardium. However, to the best of
our knowledge, this is the first report of miR-98 down-
regulation in human MI, which has been shown to be
involved in regulation of cardiac hypertrophy [34], and
its role in MI was proposed also through inflammation,
although the verification still lacks [35]. Using Sybr
Green the differential expression was shown for miR-21,
which is deregulated in numerous cardiac diseases
Boštjančič et al. BMC Genomics 2012, 13:552 Page 10 of 14
http://www.biomedcentral.com/1471-2164/13/552[24,36-38], although the role of miR-21 in cardiac path-
ology is controversial at present. miR-21 is broadly
expressed in multiple tissue, expression in the heart cells
is developmental and age-dependent [36], there is differ-
ence in expression between infracted regions and border
zone [36] as well as in cell type (cardiomyocytes, fibro-
blasts, etc.) [39]. We also showed down-regulation of
miR-126, which plays an important role in ischemic
angiogenesis [40], miR-125a/b, which are involved
(according to TAM) in myocardial remodelling after MI,
although their target genes in cardiovascular pathology
are not known at the present.
In addition, we showed that the expression analysis
using TaqMan or Sybr Green gave similar results. We
also showed that analysis of RNAlater and FFPE with
TaqMan gives the same results, which was also partially
examined in our previous study [33]. In addition, ana-
lysis of RNAlater and FFPE with Sybr Green is compar-
able. However, some discrepancies can be seen between
RNAlater and FFPE samples, and this can be due to
sampling error. FFPE tissues are microscopically exam-
ined before cutting for subsequent RNA isolation, but
this cannot be performed when using RNAlater stored
samples. Further, normalization strategy in qPCR experi-
ments (often used for validation of microarray results) is
in addition to the recent study [41] also important for
the outcome of miRNA expression analysis in the
human MI. Based on our experience, the best RG would
be RNU6B, especially when using Sybr Green. In accord-
ance to our previous studies [11,33], miR-26b is as good
RG, but only when using TaqMan technology.
Conclusion
It has been recently shown, that miRNAs are important
regulators of calcium handling subunits, and might be
also involved in regulation of calcium pumps [42,43].
Moreover, a correlation between SERCA2 expression
and miRNAs has been demonstrated [44], and in ac-
cordance to that study is also our observation that
more predicted binding sites are in SERCA2b than in
SERCA2a. Although is hard to predict, which miRNA
is involved in SERCA2 regulation, since the differen-
tially expressed miRNA can be also from non-cardio-
myocytes, we identified some good candidate miRNAs,
which could be involved in the SERCA2 regulation
(miR-199a for SERCA2b, miR-140 for both isoforms,
and miR-574 for SERCA2a). The best candidate is miR-
574-3p, which was also predicted to target SERCA2 in
our previous study [11]. In contrast to SERCA2, which
was down-regulated, both miR-574-3p and -5p showed
up-regulation in infarcted tissue compared to corre-
sponding remote myocardium as well as to healthy
human hearts. There was also high difference in free-
energy of binding and flanking region; seed region isalso predicted to be involved in pairing. However, these
are theoretical results based on expression patterns of
miRNAs and SERCA2 and computational algorithms,
which need to be further confirmed in vitro and/or
in vivo [45]. These results could be a starting point for us
and others for further validation and verification experi-
ments regarding miRNAs and SERCA2 interaction.
In addition, we showed that the expression analysis
using TaqMan or Sybr Green gave similar results. We
also showed that analysis of RNAlater and FFPE using
either technology is comparable. Finally, we defined that
normalization strategy is important for the outcome of
miRNA expression analysis in the human MI.
Methods
Patients and tissue samples
Our study included autopsy samples of infarcted heart
tissue and border zone, and the corresponding remote
myocardium from 6 patients with myocardial infarction
(MI), who died one week after MI. All autopsies were
performed within 24 h after death. MI was diagnosed
clinically by symptoms and/or electrocardiographic
changes, and confirmed by elevated plasma levels of
markers of cardiac necrosis. The duration of MI at the
time of death was estimated on the basis of histological
changes and clinical data. The rupture of free-wall was
observed in 2 patients. Among patients with MI, there
were 3 males and 3 females, aged 56–83 years (71.83 ±
10.83). Diabetes and arterial hypertension were recorded
in 3 and 3 patients, respectively. Three patients had
received reperfusion treatment and 2 had documented
arrhythmias.
For all six patients with MI the paired tissue samples
were from heart ventricle (infarcted tissue and remote
myocardium) and were immediately stored in RNAlater
(Ambion) as well as formalin-fixed paraffin-embedded
(FFPE).
The investigation conforms to the principles outlined
in the Helsinki Declaration. The Ethics Review Board of
the National Medical Ethics Committee (NMEC) of the
Republic of Slovenia granted approval for this research
(39/01/08).
Protein extraction
RNAlater stored tissue samples were homogenized in
RIPA buffer (50 mM Tris HCl (Merck), pH 8; 150 mM
NaCl (Merck); 1% (v/v) NP40 (USB); 0.5% sodium deox-
ycholate (Merck); 0.1% SDS (Sigma)) containing protease
inhibitors in a final concentration of 1 mM EDTA (Cal-
biochem), pH 8, 1 mM sodium orthovanadate (Santa
Cruz), 10 mM aprotinin (Sigma), 10 μg/ml leupeptin
(Sigma), 10 μg/ml antiapin (Sigma), 1 μg/ml pepstatin
(Sigma), 1 mM PMSF (Fluka). Homogenization of tissue
was performed by Polytron PT3000 (Kinematica AG),
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tion at 10.000xg and 4°C for 15 min. The supernatant
was transferred and stored at −70°C. The concentration
of proteins in the tissue homogenate was measured by
the BCA method (Nanodrop-1000, Thermo Scientific)
using the BCA protein assay (Pierce) according to the
manufacturer’s protocol.
Western blot
Twenty μg of proteins of tissue homogenate was electro-
phoresed at 150 V and 4°C for 40 min through SDS-
polyacrilamide gel (10% Tris-HEPES-SDS, Pierce). After
electrophoresis was completed and equilibration of gel
had been carried out, the proteins were electroblotted
onto a 0.45 μm nitrocellulose membrane (Pierce) for
1.5 h at 40 V and 4°C. The membrane was blocked with
5% (w/v) blocking reagent (Amersham) in TTBS buffer
(20 mM Tris (Merck), 150 mM NaCl (Merck), pH 7.4,
0.05% (v/v) Tween-20 (Sigma)) overnight at 4°C. After
blocking, the membrane was incubated with mouse anti-
SERCA2 (Santa Cruz, sc-73022) for 2 h at room
temperature, diluted 1:100 in 5% blocking reagent
(Amersham) in TTBS buffer, and mouse anti-GAPDH
(Santa Cruz, sc-69778) for 2 h at room temperature,
diluted 1:300 in 5% blocking reagent (Amersham) in
TTBS buffer. GAPDH was used as internal control gene.
Three washes for 5 min each time were performed in
TTBS buffer and the membrane was incubated with
horseradish peroxidase-conjugated anti-mouse (Santa
Cruz Biotehnology) for 2 h at room temperature, diluted
1:2000 in 5% blocking reagent (Amersham) in TTBS
buffer. After three more washes, ECL detection by ECL
Western Blotting Substrate (Pierce) and Hyperfilm ECL
(Amersham) was performed according to the manufac-
turer’s protocol.
miRNA isolation and analysis of extracted miRNA
RNA isolation from RNAlater stored tissue samples
Autopsy samples stored in RNAlater (Ambion) were
used for RNA extraction according to manufacturer
protocol. Total RNA isolation was performed using a
miRNeasy kit (Qiagen) according to the manufacturer’s
protocol. All the reagents were from Qiagen, except
where otherwise indicated. Briefly, the tissue was
homogenized by Polytron PT3000 (Kinematica AG) in
1 ml of QIAzol Lysis Reagent, following addition of
200 μl of chloroform and centrifugation for 15 min at
12.000xg. After addition of 100% ethanol (Merck, USA)
to the aqueous phase the mixture was transferred to an
RNeasy Mini spin column. Three washing steps were
further performed (using buffers RWT and RPE) as
well as on-column DNase digestion (RNase-Free DNase
Set). The RNA was eluted in 50 μl of nuclease-free
water.RNA isolation from FFPE tissue samples
Three to eight 10-μm sections were used for the isola-
tion procedure. Total RNA isolation was performed
using a miRNeasy FFPE kit (Qiagen) according to the
manufacturer’s protocol. All the reagents were from Qia-
gen, except where otherwise indicated. Briefly, 1 ml of
Xylene (Merck) was added for de-paraffinization, fol-
lowed by brief vortexing and centrifugation. After the
ethanol-washing step (using 1 ml of 100% ethanol), pel-
lets were air-dried and digestion with Proteinase K in
0.25 ml digestion mix was performed at 55°C for
15 min. Further, 15 min incubation at 80°C in order to
partially reverse formaldehyde modification of nucleic
acid was performed. After adding 0.5 ml of RBC buffer
and gDNA elimination step, 1.75 ml of 100% ethanol
(Merck) was added to the eluted samples and the mix-
ture was transferred to an RNeasy MiniElute spin col-
umn. After two washing steps (using buffer RPE), the
RNA was eluted in 30 μl of nuclease-free water.
Concentration and integrity measurements of extracted
RNA
The concentration of the extracted RNA was measured
using NanoDrop-1000 (Thermo Scientific) and tested
for UV/vis ratios. The A260/A230 nm intensity ratio
needs to be above 1.0 and A260/A280 ratio needs to be
above 1.8. The integrity and presence of small RNAs
(<200 nucleotides) was analyzed on a Bioanalyzer 2100
(Agilent) using the high resolution Small RNA Assay.
microRNA microarray analysis
Expression analysis was performed using hybridization
to μParafloW microfluidics micorarrays (LC Sciences) in
the Sanger miRBase database Release 10.1 (719 predicted
mature human miRNA probes, MRA-1001), and spike-
in/perfectly matched and mismatched probes for quality
control. Each miRNA probe was represented 5 times on
a single microarray. The control probes were spiked into
the RNA samples before labelling. Five to ten μg of RNA
from heart samples was used for miRNA microarray.
Using size-fractionation, small RNA (<300 nt) enrich-
ment was performed, following extension with a poly(A)
tail, to which the an oligonucleotide tag was added for
subsequent labelling. The two sets of RNA sequences
were labelled with different affinity tags to allow simul-
taneous detection of two samples using dual colour label-
ling (Cy3 and Cy5) and dye-reversal. Three microRNA
microarrays were performed, using RNA samples from
3 infarcted tissues and compared to 3 corresponding re-
mote myocardium.
To detect small amounts of miRNA, standard data
analysis was performed (calculation of signal intensities,
determination of detectable transcripts, and calculation
of differential ratios). The signal was amplified and the
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method. Spot signals normalization was carried out
using a cyclic LOWESS (Locally-weighted regression)
method (resulting in so-called processed data). The
miRNAs were treated as detected, when the signals of
the repeating probes were above detection level in at
least 3 of 5 probes for each miRNA. For the dual colour
experiment, the ratio of the two sets of detected signals
(Log2 transformed, balanced) and p-values of the t-test
were calculated; differentially detected signals were those
with less than 0.01 of p-values. All data processes are
carried out using in-house developed computer pro-
grams by LC sciences. Data adjustment includes data fil-
tering, Log2 transformation, and gene centring and
normalization. miRNAs with intensity values below a
threshold value (data filtering) were removed and log2
transformation was used to convert expression values
into a linear scale for statistical comparison. Gene centring
and normalization transform the Log2 values using the
mean and the standard deviation of individual genes across
all samples.
Further microarray analysis using processed data and
the Acuity 4.0 program defined which miRNAs were dif-
ferently expressed in all of the microarrays performed
(infarcted tissue compared to corresponding remote
myocardium). MiRNA expression heat map was con-
structed by unsupervised hierarchical clustering to reveal
the relationship between differentially expressed miRNAs.
Bioinformatics analysis and miRNA prediction
SERCA2:miRNA prediction
To investigate SERCA2 mRNA as a target for miRNA
regulation, 3'-UTRs mRNA sequences of corresponding
SERCA2a and SERCA2b were analyzed by various com-
putational algorithms, which utilize distinct parameters
to predict the probability of a functional miRNA-binding
site within a given mRNA target. We used the following
bioinformatic algorithms to predict miRNA target sites:
PicTar [13], TargetScan5.1 [12], mirTarget2 included in
miRDB [14], and miRanda [15] included in databases
miRBase (MicroCosm Targets) [16] and in microrna.org
[17].
SERCA2a:miRNA free-energy binding analysis
To further investigate the putative miRNAs (up-regu-
lated miRNAs in infracted tissue) that may repress the
expression of mRNA SERCA2, we performed in silico
free-energy validation. We determined the free-energy
(ΔG) of the miRNA:mRNA binding, using the RNA22
algorithm [19], and ΔG 70 nt flanking the 5' and 3' sides
of the predicted miRNA binding sites, using RNAfold
[20]. According to Zhao et al. (2005) [18] we tested the
following presumptions to verify the miRNA as potential
regulator of SERCA2: (i) if miRNAs seed regions areinvolved in binding; (ii) we calculated the free-energy
of binding SERCA2a:miRNAs and 70 nt flanking the 5'
and 3' sides. Sequences for 3-UTR SERCA2a and
SERCA2b were downloaded from NCBI, accession
numbers NM_001681.3 and NM_170665.3, respectively,
and from Ensembl, transcript ID ENST00000313432 and
ENST00000308664, respectively.
miRNA annotation and functional classification
Using miRBase [16] the differentially expressed miRNAs
were searched for genomic location, clusters and miRNA
Gene family. TAM tool [21] was used to annotate differ-
entially expressed miRNAs in the mean of function and
disease associations, and miRNApath [22] was used to
search for miRNAs that may be involved in calcium sig-
nalling pathway, and could regulate two other proteins
that regulate SERCA2 expression, phosphlamban (PLN)
and sarcolipin (SLN).
Quantitative real-time PCR (qPCR)
Some miRNAs differentially expressed in miRNA micro-
array expression analysis were validated using the miS-
cript system (Qiagen) or TaqMan based technology
(Applied Biosystems). All the reagents were from Qiagen
or Applied Biosystems, respectively, except where other-
wise indicated. qPCR was carried out using the Rotor
Gene Q (Qiagen) or ABI 7900 Real-Time PCR System
(Applied Biosystems).
Prior to qPCR analysis two pools of RNA samples
were created, obtained from RNAlater stored and FFPE
tissue samples. After reverse transcription, the cDNA
was diluted in five steps, ranging from 3-fold dilution to
243-fold dilution, and the probes were tested for PCR ef-
ficiency. All the qPCR efficiency reactions were per-
formed in triplicate.
miScript System (Qiagen)
No-reverse transcriptase (no-RT) control included all
the qPCR reagents without the reverse transcription
(RT) step. If the product was amplified, it indicated
that there was still some genomic DNA contamination.
Using DNA digestion step, the RNA obtained from
heart tissue samples was treated with DNAse I (RNase-
Free DNase Set, Qiagen) prior to qPCR, if the product
was amplified during no-RT control. Up to 1 μg (5 μl)
of RNA contaminated with genomic DNA was used,
adding 2 μl 10x DNase buffer (RDD buffer), 10 units
RNase inhibitor, 0.5 Kunitz units DNase I and RNase-
free water to obtained 20 μl reaction mixtures. After
30 min incubation step at 37°C, 2 μl 140 mM EDTA
(Sigma) was added and incubate for 5 min at 65°C to
inactivate DNase I. Concentration was measured again
using NanoDrop-1000. An miScript reverse transcrip-
tion kit was used for RT. Briefly, a 15 μl reaction
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RNA, 3 μl 5x miScript RT buffer, 0.75 μl miScript re-
verse transcriptase mix and 10 units (0.33 μl) RNase
inhibitor. After incubation for 60 min at 37°C and
5 min at 95°C, the cDNA was diluted 10-fold, and 3 μl
was used for each qPCR reaction. Ten μl PCR master
mix contained 5 μl 2x QuantiTect SYBR Green PCR
Master Mix, 1 μl 10x miScript universal primer and
1 μl 10x miScript Primer Assay. All the qPCR reactions
were performed in duplicate as following: initial de-
naturation at 95°C for 15 min, and 40 cycles for 15 s at
94°C (denaturation), for 30 s at 55°C (primers anneal-
ing), and for 30 s at 70°C (elongation). Following amp-
lification, melting curves were acquired on the SYBR
channel using a ramping rate of 1°C/60 s for 60–95°C.
MicroRNAs, miR-122, miR-125a-5p, miR-125b, miR-
126, miR-21 were tested relatively to RNU6B and miR-
26b. RNU6B and miR-26b were tested as the RGs. The
signal was collected at the endpoint of every cycle.TaqMan based technology
Looped primers for specific miRNA RT were utilized
following the manufacturer’s protocol. RNU6B, RNU48
and miR-26b were used as RGs, according to the man-
ufacturer’s protocol. MicroRNAs, miR-1, miR-133a,
miR-133b, and miR-98 were tested relatively to
RNU6B, RNU48 and miR-26b. Briefly, the 10 μl RT re-
action master mix was performed with 10 ng of total
RNA sample, 0.71 μl of MultiScribe Reverse Tran-
scriptase (50 U/μl), 1 μl of Reverse Transcription Buf-
fer (10x), 0.1 μl of dNTP (100 mM), 0.19 μl RNAase
inhibitor (20 U/μl), and 2 μl of RT primer (5x). The re-
action conditions were: at 16°C for 30 min, at 42°C for
30 min, at 85°C for 5 min. qPCR was carried out in
20 μl PCR master mix containing 10 μl TaqMan 2x
Universal PCR Master Mix, 1 μl TaqMan assay, 9 μl RT
products diluted 7-fold. The qPCR reactions were per-
formed in duplicates or triplicates as following: initial
denaturation at 95°C for 10 min, and 40 cycles for 15 s
at 95°C (denaturation), for 60 s at 60°C (primers
annealing and elongation). The signal was collected at
the endpoint of every cycle.Statistical analysis
For miRNA expression analysis using qPCR, the calcu-
lation based on efficiency correction was used [46].
Statistical analysis was performed using nonparametric
Willcoxon Rank test and Spermans Rho correlation co-
efficient, both of which are included in SPSS statistical
software (v20), with a cut off point at p < 0.05. When
the differences in ratio of tested groups reached or
were below p = 0.05, the difference in miRNA expres-
sion was considered as statistical significant.Additional files
Additional file 1: Table S1. Predicted miRNAs to target SERCA2
according to the used programs.
Additional file 2: Table S2. Annotation of differentially expressed
miRNAs using TAM tool – functions.
Additional file 3: Table S3. Annotation of differentially expressed
miRNAs using TAM tool - disease association (HMDD) related to heart
diseases, development and physiology.
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